000			01352 a2200349 4500
005			20250514061057.0
264		0	_c20030411
008			200304s 0 0 eng d
022			_a1040-8711
024	7		_a10.1097/00002281-200303000-00006 _2doi
040			_aNLM _beng _cNLM
100	1		_aSolomon, Daniel H
245	0	0	_aPharmacoepidemiology and rheumatic diseases: 2001-2002. _h[electronic resource]
260			_bCurrent opinion in rheumatology _cMar 2003
300			_a122-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aAntirheumatic Agents _xadverse effects
650	0	4	_aCyclooxygenase Inhibitors _xadverse effects
650	0	4	_aFemale
650	0	4	_aGlucocorticoids _xadverse effects
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xadverse effects
650	0	4	_aMale
650	0	4	_aPharmacoepidemiology
650	0	4	_aRheumatic Diseases _xdiagnosis
650	0	4	_aRisk Assessment
650	0	4	_aSensitivity and Specificity
700	1		_aAvorn, Jerry
773	0		_tCurrent opinion in rheumatology _gvol. 15 _gno. 2 _gp. 122-6
856	4	0	_uhttps://doi.org/10.1097/00002281-200303000-00006 _zAvailable from publisher's website
999			_c12395589 _d12395589